Lyphe Launches Noidecs V Range: Affordable, Reliable, and Future-Ready Medical Cannabis
Lyphe is proud to introduce the Noidecs V Range, a new line of medical cannabis products that simplifies treatment options for patients while addressing the biggest challenges in the UK market, affordability, accessibility, and supply chain resilience.
This new product line focuses on therapeutic properties, such as cannabinoids and terpenes, ensuring patients receive safe, effective care, consistent and stable treatment without the complexity of traditional strain names.
Why the Noidecs V Range is Needed
The UK medical cannabis market has grown rapidly since its legalisation in 2018. However, many patients still face significant barriers to care, including:
- High treatment costs that make long-term care unsustainable.
- Confusion over strain names, which can complicate decision-making for patients and clinicians alike.
- Supply chain issues leading to delayed access to medication.
The Noidecs V Range was created to tackle these challenges directly by offering affordable, consistent, and transparent medical cannabis options that focus on what truly matters: therapeutic outcomes.
Key Benefits of the Noidecs V Range
- Simplified Treatment Choices
By shifting focus to therapeutic properties like cannabinoids and terpenes, the Noidecs V Range eliminates the confusion often associated with strain names. This approach helps both new and experienced patients find the right treatment more easily, while ensuring clinicians can confidently prescribe medication tailored to individual needs. - Affordable and Accessible Care
Designed with patients’ budgets in mind, the Noidecs V Range reduces production inefficiencies by repurposing high-quality batches that meet strict safety and therapeutic standards. These savings are passed directly to patients, ensuring consistent, affordable access to care without compromising quality. - Reliable Supply Chain
Supply chain disruptions have long plagued the UK medical cannabis market. The Noidecs V Range introduces a sustainable production model that ensures consistent availability of medication, even amid regulatory and logistical challenges. By reducing waste and stabilising supply, Lyphe aim is to ensure that patients can rely on their treatments without interruption.
A Transparent and Sustainable Approach
Every batch is supported by detailed Certificates of Analysis (COAs), providing clear information on cannabinoid and terpene profiles. These COAs are accessible via our product formulary, or via any prescribing Dr which ensures both patients and clinicians can make informed decisions about their care. Currently, the Noidecs V range is available exclusively to patients through Lyphe Dispensary. However, as the range expands, Lyphe aims to make these products accessible through all pharmacies, further improving patients’ access and choice.
The Noidecs V Range also reflects Lyphe’s commitment to sustainability. By utilising safe, effective batches that may not meet narrow strain-specific branding criteria, the Noidecs V Range reduces environmental waste and strengthens the medical cannabis supply chain.
For each iteration of a single Noidecs V line where the cultivar changes, we will distinguish the new batch by adding on a unique letter for instance: ‘Noidecs VThree A’. Naturally for each batch released there will be corresponding COA’s and patient information sheets available to reference the change in cultivar. This innovation sets a new standard for responsible production in the industry.
A Globally Proven Approach
The approach adopted for the Noidecs V Range is not unique to the UK. Across international medical cannabis markets, focusing on therapeutic properties like cannabinoids and terpenes has proven to simplify prescribing, improve patient access, and ensure consistency in care.
This simplified approach has also been incredibly popular with patients, who value the clarity it brings to their treatment journey and trust the Doctors to prescribe the most suitable strain for their condition. By focusing on the expertise of clinicians and the therapeutic properties of each product, the Noidecs V range ensures patients receives care that is tailored to their needs while building confidence in the prescribing process.
By aligning with this global trend, the Noidecs V Range brings the UK in step with modern medical cannabis practices, ensuring patients benefit from a forward-thinking approach that prioritises outcomes and sustainability.
Supporting All Patients
Lyphe recognises that no two patients are the same. For those who prefer strain-specific products, these options remain available alongside the Noidecs V Range. This dual approach ensures that every patient has access to treatments that align with their preferences and therapeutic needs.
The Noidecs V range has been developed in consultation with doctors and patient teams to ensure it meets the highest standards of care and aligns with the needs of all stakeholders. Since its launch, nearly 600 10g units have been dispensed, demonstrating its growing acceptance and effectiveness in the patient community.
The Noidecs V Range is not a replacement, it is a quality, affordable addition, expanding the choices available to patients while paving the way for a more reliable, patient-focused future.
Looking Ahead: Modernising Medical Cannabis
The Noidecs V Range is part of a larger shift in the ever evolving medical cannabis industry towards standardisation and modernisation. By focusing on therapeutic outcomes and aligning with Medicines and Healthcare products Regulatory Agency (MHRA) guidelines, Lyphe is helping to shape a future where medical cannabis is as straightforward and consistent as any other regulated medicine.
This approach ensures patients receive care that is safe, effective, and aligned with the highest standards of quality.
A Message to Our Patients
We understand that change can bring questions and concerns. The Noidecs V Range was developed with one goal in mind: to make medical cannabis simpler, more affordable, and more reliable for everyone. For those who value strain-specific products, those options remain available.
If you have questions about the Noidecs V Range or your treatment options, we invite you to contact us directly. Your care and trust are our top priorities.
About Lyphe
Lyphe is a leader in the UK medical cannabis industry, dedicated to improving patient
outcomes through innovative products, trusted care models, and deep regulatory expertise. By prioritising accessibility, affordability, and sustainability, Lyphe is shaping the future of medical cannabis for patients across the country.
For more information about the Noidecs V Range or to speak with a member of our team, visit https://lyphedispensary.com
For more details on Lyphe Clinc or to learn more about Lyphe’s product CBD line, click here.
For media inquiries, contact Becky McLaren, Marketing Manager, at: becky.mclaren@lyphe.com
Book an online appointment
Lyphe is your patient-first path to wellness, so book an appointment with one of our medical cannabis expert Doctors and get the relief you need.
Disclaimer
The content provided on this blog is intended for educational purposes only and should not be construed as medical advice. We strongly advise readers to seek guidance from a qualified healthcare professional regarding any medical concerns.
To reflect its medicinal nature rather than recreational use, we prefer the term ‘medical cannabis’ over terms such as ‘marijuana’, “grass”. or ‘dope’ which may carry negative connotations.
The opinions expressed in the blog belong to the respective authors, who are not medical professionals, and may not necessarily align with those of Lyphe Clinic. Lyphe Clinic does not endorse any specific products or services mentioned, except those provided through Lyphe Clinic.
Readers should be aware that the legality of medical cannabis varies by location, and this disclaimer may be subject to periodic updates.
Related Insights
Whilst you’re here you might also like to read…
